Biotech giant Amgen (AMGN +1.15%) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly, ...
Amgen (NASDAQ: AMGN) revealed that the Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system, a fresh, monthly single-dose administration option. According to the ...
BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...
Amgen Inc.AMGN announced that the FDA has approved a new, monthly single-dose administration option for its PCSK9 inhibitor, Repatha. The Repatha Pushtronex system, an on-body infusor with a prefilled ...
THOUSAND OAKS, Calif., Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha ® (evolocumab) Pushtronex ™ system (on-body infusor with prefilled cartridge), a ...
Please provide your email address to receive an email when new articles are posted on . The product is indicated as an adjunct therapy for adults with heterozygous familial hypercholesterolemia or ...
Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...
Biotech giant Amgen (NASDAQ: AMGN) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly, ...
The FINANCIAL — Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a new, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results